JP2018521014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521014A5 JP2018521014A5 JP2017561811A JP2017561811A JP2018521014A5 JP 2018521014 A5 JP2018521014 A5 JP 2018521014A5 JP 2017561811 A JP2017561811 A JP 2017561811A JP 2017561811 A JP2017561811 A JP 2017561811A JP 2018521014 A5 JP2018521014 A5 JP 2018521014A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- amyloidosis
- disease
- group
- trim
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021155978A JP2022000459A (ja) | 2015-05-29 | 2021-09-24 | ミスフォールドタンパク質の分解のための組成物及び方法 |
| JP2024135688A JP2024161501A (ja) | 2015-05-29 | 2024-08-15 | ミスフォールドタンパク質の分解のための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168309P | 2015-05-29 | 2015-05-29 | |
| US62/168,309 | 2015-05-29 | ||
| PCT/US2016/034751 WO2016196328A1 (en) | 2015-05-29 | 2016-05-27 | Compositions and methods for degradation of misfolded proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021155978A Division JP2022000459A (ja) | 2015-05-29 | 2021-09-24 | ミスフォールドタンパク質の分解のための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521014A JP2018521014A (ja) | 2018-08-02 |
| JP2018521014A5 true JP2018521014A5 (https=) | 2019-06-20 |
| JP7011467B2 JP7011467B2 (ja) | 2022-02-10 |
Family
ID=57441753
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017561811A Active JP7011467B2 (ja) | 2015-05-29 | 2016-05-27 | ミスフォールドタンパク質の分解のための組成物及び方法 |
| JP2021155978A Pending JP2022000459A (ja) | 2015-05-29 | 2021-09-24 | ミスフォールドタンパク質の分解のための組成物及び方法 |
| JP2024135688A Pending JP2024161501A (ja) | 2015-05-29 | 2024-08-15 | ミスフォールドタンパク質の分解のための組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021155978A Pending JP2022000459A (ja) | 2015-05-29 | 2021-09-24 | ミスフォールドタンパク質の分解のための組成物及び方法 |
| JP2024135688A Pending JP2024161501A (ja) | 2015-05-29 | 2024-08-15 | ミスフォールドタンパク質の分解のための組成物及び方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11542500B2 (https=) |
| EP (1) | EP3302706A4 (https=) |
| JP (3) | JP7011467B2 (https=) |
| KR (2) | KR20240108531A (https=) |
| CN (1) | CN108271364A (https=) |
| AU (3) | AU2016271635B2 (https=) |
| BR (1) | BR112017025574A2 (https=) |
| CA (1) | CA2987057A1 (https=) |
| HK (1) | HK1252757A1 (https=) |
| IL (3) | IL255912B2 (https=) |
| MX (3) | MX2017015373A (https=) |
| RU (2) | RU2021134920A (https=) |
| SG (1) | SG10202011833TA (https=) |
| WO (1) | WO2016196328A1 (https=) |
| ZA (1) | ZA201708067B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| CA3193811A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| CN119876138A (zh) | 2014-11-14 | 2025-04-25 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| CA3024448C (en) | 2016-05-18 | 2025-09-09 | Voyager Therapeutics, Inc. | MODULATING POLYNUCLEOTIDES |
| CN110753557B (zh) * | 2017-03-22 | 2024-03-22 | 神济昌华(北京)生物科技有限公司 | Trim72通过泛素化fus蛋白突变体作为als的潜在治疗性靶标 |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CN109609614B (zh) * | 2017-09-30 | 2022-07-15 | 首都医科大学附属北京胸科医院 | 检测trim2、trim4、trim32和/或trim46基因或蛋白产品的用途 |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| CN108018303A (zh) * | 2017-12-20 | 2018-05-11 | 江苏浩欧博生物医药股份有限公司 | 一种人Ro52重组蛋白的制备方法 |
| WO2019175881A1 (en) | 2018-03-14 | 2019-09-19 | Technion Research & Development Foundation Limited | A prognostic biomarker in cancer |
| SG11202011296VA (en) | 2018-05-15 | 2020-12-30 | Voyager Therapeutics Inc | Compositions and methods for the treatment of parkinson's disease |
| US11147815B2 (en) | 2018-08-21 | 2021-10-19 | Synkrino Biotherapeutics, Inc. | Compositions and methods for treating diseases associated with uncontrolled inflammatory responses |
| EP3863642A4 (en) * | 2018-10-09 | 2022-06-29 | The Regents of the University of California | Covalent targeting of e3 ligases |
| WO2020227515A1 (en) * | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| CN110302383A (zh) * | 2019-07-29 | 2019-10-08 | 深圳先进技术研究院 | Trim11基因和蛋白靶点以及抑制剂在乳腺癌中的用途 |
| CN110669791B (zh) * | 2019-10-29 | 2020-08-04 | 成都益安博生物技术有限公司 | 一种提高细胞抗体表达量的方法 |
| KR102114880B1 (ko) * | 2020-01-15 | 2020-05-26 | 서울대학교병원 | 코돈 최적화된 TIF1γ 폴리뉴클레오티드를 포함하는 재조합 벡터 및 이의 용도 |
| GB202005876D0 (en) * | 2020-04-22 | 2020-06-03 | Univ Dundee | Protein degradation |
| WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| CN113292658B (zh) * | 2021-04-17 | 2023-02-28 | 复旦大学 | 一种融合蛋白及其在靶向降解细胞内蛋白中的应用 |
| CN113651879A (zh) * | 2021-08-18 | 2021-11-16 | 武汉华美生物工程有限公司 | 一种trim21全长蛋白的制备方法及应用 |
| CN117159747B (zh) * | 2023-08-30 | 2024-12-20 | 暨南大学 | 一种亨廷顿舞蹈症的药物及其制备方法 |
| CN118272444A (zh) * | 2024-02-29 | 2024-07-02 | 宜昌市中心人民医院(三峡大学第一临床医学院、三峡大学附属中心人民医院) | 一种慢病毒载体LV-Trim69及其在制备改善心脏衰老药物上的应用 |
| CN120209082B (zh) * | 2025-05-28 | 2025-08-05 | 中南大学 | 一种靶向阻断trim25与brd7蛋白结合的多肽及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010027182A1 (en) * | 1998-05-29 | 2001-10-04 | Huda Y. Zoghbi | Chaperone suppression of ataxin-1 aggregation and altered subcellular proteasome localization imply protein misfilind in sca1 |
| WO2001090342A2 (en) | 2000-05-22 | 2001-11-29 | Johns Hopkins University | Genetic engineering of vascular grafts to resist disease |
| US20040235733A1 (en) * | 2003-02-27 | 2004-11-25 | Steffan Joan S. | Methods and reagents for reducing polyglutamine toxicity |
| US20050215562A1 (en) * | 2003-06-23 | 2005-09-29 | Patrick Tremblay | Methods for treating protein aggregation disorders |
| WO2005081911A2 (en) * | 2004-02-25 | 2005-09-09 | Dana-Farber Cancer Institute, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HIV INFECTION USING TRIM5α |
| US20140056873A1 (en) | 2004-06-10 | 2014-02-27 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| WO2006116716A2 (en) * | 2005-04-27 | 2006-11-02 | University Of Florida | Materials and methods for enhanced degradation of mutant proteins associated with human disease |
| EP1870107A1 (en) * | 2006-06-23 | 2007-12-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of inducer of promyelocytic leukemia protein (PML) for treating polyglutamine expansion neurodegenerative diseases |
| US7785857B2 (en) | 2006-08-31 | 2010-08-31 | Saint Louis University | Protein C variant |
| CA2749163A1 (en) | 2009-01-14 | 2010-07-22 | The Salk Institute For Biological Studies | Methods for screening and compounds that protect against amyloid diseases |
| EP2826860B1 (en) * | 2010-04-23 | 2018-08-22 | University of Massachusetts | CNS targeting AAV vectors and methods of use thereof |
| GB201012410D0 (en) * | 2010-07-23 | 2010-09-08 | Medical Res Council | Intracellular immunity |
| AU2011295629B2 (en) | 2010-09-01 | 2014-05-01 | Organ Transport Pty Ltd | Perfusion composition |
| CN103127492A (zh) * | 2011-11-23 | 2013-06-05 | 中国科学院上海巴斯德研究所 | 一种抗丙型肝炎病毒的蛋白及其用途 |
| TR201905612T4 (tr) * | 2012-12-05 | 2019-05-21 | Univ Heidelberg Ruprecht Karls | Proteinlerin ve çok değerlikli, hücreye nüfuz eden peptitlerin konjugatları ve bunların kullanımları. |
| US20160136123A1 (en) * | 2013-06-14 | 2016-05-19 | Vojo P. Deretic | Treatment of autophagy-related disorders |
| WO2016054554A1 (en) * | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Heterologous targeting peptide grafted aavs |
-
2016
- 2016-05-27 US US15/577,915 patent/US11542500B2/en active Active
- 2016-05-27 BR BR112017025574-0A patent/BR112017025574A2/en not_active Application Discontinuation
- 2016-05-27 EP EP16804142.4A patent/EP3302706A4/en active Pending
- 2016-05-27 AU AU2016271635A patent/AU2016271635B2/en active Active
- 2016-05-27 CA CA2987057A patent/CA2987057A1/en active Pending
- 2016-05-27 RU RU2021134920A patent/RU2021134920A/ru unknown
- 2016-05-27 IL IL255912A patent/IL255912B2/en unknown
- 2016-05-27 HK HK18112082.4A patent/HK1252757A1/zh unknown
- 2016-05-27 JP JP2017561811A patent/JP7011467B2/ja active Active
- 2016-05-27 SG SG10202011833TA patent/SG10202011833TA/en unknown
- 2016-05-27 WO PCT/US2016/034751 patent/WO2016196328A1/en not_active Ceased
- 2016-05-27 RU RU2017144862A patent/RU2761564C9/ru active
- 2016-05-27 CN CN201680044063.4A patent/CN108271364A/zh active Pending
- 2016-05-27 KR KR1020247021052A patent/KR20240108531A/ko active Pending
- 2016-05-27 IL IL322085A patent/IL322085A/en unknown
- 2016-05-27 MX MX2017015373A patent/MX2017015373A/es unknown
- 2016-05-27 IL IL302965A patent/IL302965B2/en unknown
- 2016-05-27 KR KR1020177037891A patent/KR20180011276A/ko not_active Ceased
-
2017
- 2017-11-28 ZA ZA2017/08067A patent/ZA201708067B/en unknown
- 2017-11-29 MX MX2024001616A patent/MX2024001616A/es unknown
- 2017-11-29 MX MX2021014954A patent/MX2021014954A/es unknown
-
2021
- 2021-09-24 JP JP2021155978A patent/JP2022000459A/ja active Pending
-
2022
- 2022-02-02 AU AU2022200673A patent/AU2022200673B2/en active Active
- 2022-11-21 US US18/057,308 patent/US20230313190A1/en active Pending
-
2024
- 2024-08-15 JP JP2024135688A patent/JP2024161501A/ja active Pending
-
2025
- 2025-09-09 AU AU2025230665A patent/AU2025230665A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521014A5 (https=) | ||
| Bez Batti Angulski et al. | Duchenne muscular dystrophy: disease mechanism and therapeutic strategies | |
| RU2017144862A (ru) | Композиции и способы деградации неправильно упакованных белков | |
| US20200149068A1 (en) | Chimeric capsids | |
| KR102599909B1 (ko) | 근위축성 측삭 경화증(als)을 치료하는 조성물 및 방법 | |
| Amantana et al. | Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide− morpholino oligomer conjugate | |
| CN113631225A (zh) | 用于生产aav颗粒的方法和系统 | |
| TW201905200A (zh) | 調節多核苷酸 | |
| KR20250025387A (ko) | Aav 캡시드 변이체 및 이의 용도 | |
| JP2018506980A5 (https=) | ||
| US20150141320A1 (en) | Compositions and methods for modulating gene expression | |
| Meneghini et al. | Delivery platforms for CRISPR/Cas9 genome editing of glial cells in the central nervous system | |
| TW201534719A (zh) | 用於杜顯氏肌肉萎縮症（ｄｍｄ）之多重外顯子跳躍組合物 | |
| US20230399642A1 (en) | Compositions and methods of treating huntington's disease | |
| US20220411821A1 (en) | Gene therapy vectors | |
| US10900041B2 (en) | Antisense oligonucleotides for use in treating Alzheimer's disease | |
| WO2018021855A1 (ko) | Cas9 단백질 및 가이드 RNA를 포함하는 안질환 치료용 약학 조성물 | |
| Devaney et al. | Clinical review: gene-based therapies for ALI/ARDS: where are we now? | |
| BR112021008832A2 (pt) | Proteínas de núcleo de mininucleossoma e uso em distribuição de ácido nucleico | |
| TW202424201A (zh) | Ａａｖ殼體變異體及其用途 | |
| JP2023529371A (ja) | シヌクレイノパチーの処置のための組成物および方法 | |
| Passineau | Salivary gland gene therapy in experimental and clinical trials | |
| EP3914240A1 (en) | Tfap2 inhibition for treating cardiac disease involving fibro-fatty replacement | |
| EP4100067A1 (en) | Mirna-485 inhibitor for gene upregulation | |
| Singh et al. | Targeted delivery for neurodegenerative disorders using gene therapy vectors: Gene next therapeutic goals |